61 related articles for article (PubMed ID: 37585673)
1. Lichenoid dermatitis preceding Stevens-Johnson syndrome in a patient treated with nivolumab.
Potts J; Lee RR; Hilliard CA
BMJ Case Rep; 2022 Aug; 15(8):. PubMed ID: 36028237
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors.
Storgard R; Markova A
J Allergy Clin Immunol Pract; 2024 May; 12(5):1132-1136. PubMed ID: 38548170
[TBL] [Abstract][Full Text] [Related]
3. Comment on "Toxic epidermal necrolysis during camrelizumab treatment for oesophageal squamous cell carcinoma".
Ruan Y; Shih Y; Chen S; Xia Q; Zhao X; Cao H
Contact Dermatitis; 2022 Oct; 87(4):387-388. PubMed ID: 35762304
[No Abstract] [Full Text] [Related]
4. Afatinib-induced toxic epidermal necrolysis: A case report with a literature review.
Belančić A; Hlača N; Peternel S; Golčić M; Prpić-Massari L; Vlahović-Palčevski V
Br J Clin Pharmacol; 2024 May; ():. PubMed ID: 38803188
[TBL] [Abstract][Full Text] [Related]
5. Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review.
Xiong W; Yang Z; Chen Y
Immunotherapy; 2024 Mar; ():. PubMed ID: 38530080
[TBL] [Abstract][Full Text] [Related]
6. The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.
Pach J; Valido K; Belzer A; Leventhal JS
Am J Clin Dermatol; 2024 May; ():. PubMed ID: 38767827
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of borneol-gypsum in skin regeneration and pain control in toxic epidermal necrolysis: A case report.
Yang LW; Zhang LJ; Zhou BB; Lin XY; Chen YT; Qin XY; Tian HY; Ma LL; Sun Y; Jiang LD
World J Clin Cases; 2024 Mar; 12(7):1290-1295. PubMed ID: 38524518
[TBL] [Abstract][Full Text] [Related]
8. A Case of Punctate Psoriasis Following Treatment with Cetuximab in a Patient with Metastatic Gastric Adenocarcinoma.
Fan J; Gong Y; Yang G
J Inflamm Res; 2024; 17():2633-2637. PubMed ID: 38707959
[TBL] [Abstract][Full Text] [Related]
9. Emerging Insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy.
Lin M; Gong T; Ruan S; Lv X; Chen R; Su X; Cheng B; Ji C
J Inflamm Res; 2024; 17():2337-2351. PubMed ID: 38645875
[TBL] [Abstract][Full Text] [Related]
10. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
11. Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report.
Li G; Gong S; Wang N; Yao X
Front Immunol; 2022; 13():989966. PubMed ID: 36090976
[TBL] [Abstract][Full Text] [Related]
12. Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature review.
Zhang L; Wang L; Cheng Q; Lei X; Wu J; Chen N
Immunotherapy; 2023 Oct; 15(15):1249-1256. PubMed ID: 37585673
[TBL] [Abstract][Full Text] [Related]
13. Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review.
Yang W; Xu X; Xia D; Wang H; Jiang J; Yang G
Immunotherapy; 2022 Apr; 14(5):275-282. PubMed ID: 35128931
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
15. Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature.
Emonet C; Tétart F; Bauvin O; Cellier L; Courville P; Mignard C; Janela-Lapert R; Lefebvre A; Lachkar S; Lechevalier D; Lagarce L; Carvalho P; Tedbirt B
J Immunother; 2023 Feb-Mar 01; 46(2):59-63. PubMed ID: 36622668
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
